Key Efficacy and Safety Data from the EMERALD Trial

Elacestrant achieved a statistically significant improvement in progression-free survival compared to standard endocrine therapy, especially among patients with ESR1 mutations, where it reduced the risk of disease progression or death by 45%. Common adverse events included mild to moderate nausea, with no grade 4 events reported. The safety profile was considered manageable and consistent with endocrine-based therapy expectations.